Clarity Pharmaceuticals' 64Cu-SAR-bisPSMA Doubles Prostate Cancer Detection in Head-to-Head Trial

Reuters

Feb 16

<a href="https://laohu8.com/S/CU6.AU">Clarity Pharmaceuticals</a>' 64Cu-SAR-bisPSMA Doubles Prostate Cancer Detection in Head-to-Head Trial

Clarity Pharmaceuticals Ltd. announced that data from the Co-PSMA Investigator-Initiated Trial (IIT), evaluating its diagnostic product 64Cu-SAR-bisPSMA in comparison to standard-of-care 68Ga-PSMA-11, will be presented at the European Association of Urology (EAU) Congress 2026. The study was conducted in 50 patients with biochemical recurrence of prostate cancer following radical prostatectomy. According to the released abstract, 64Cu-SAR-bisPSMA more than doubled prostate cancer lesion and patient detection rates compared to 68Ga-PSMA-11. Further data will be outlined following the oral presentation at EAU 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clarity Pharmaceuticals Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602160903PR_NEWS_USPR_____CN88550) on February 16, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2611748526"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2611748526\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2611748526?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-16 22:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2611748526","market":"us","top_or_hot":-1,"title":"Clarity Pharmaceuticals' 64Cu-SAR-bisPSMA Doubles Prostate Cancer Detection in Head-to-Head Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CU6.AU\">Clarity Pharmaceuticals</a>' 64Cu-SAR-bisPSMA Doubles Prostate Cancer Detection in Head-to-Head Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CLRPF\">Clarity Pharmaceuticals Ltd.</a> announced that data from the Co-PSMA Investigator-Initiated Trial (IIT), evaluating its diagnostic product 64Cu-SAR-bisPSMA in comparison to standard-of-care 68Ga-PSMA-11, will be presented at the European Association of Urology (EAU) Congress 2026. The study was conducted in 50 patients with biochemical recurrence of prostate cancer following radical prostatectomy. According to the released abstract, 64Cu-SAR-bisPSMA more than doubled prostate cancer lesion and patient detection rates compared to 68Ga-PSMA-11. Further data will be outlined following the oral presentation at EAU 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clarity Pharmaceuticals Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602160903PR_NEWS_USPR_____CN88550) on February 16, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clarity Pharmaceuticals' 64Cu-SAR-bisPSMA Doubles Prostate Cancer Detection in Head-to-Head Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClarity Pharmaceuticals' 64Cu-SAR-bisPSMA Doubles Prostate Cancer Detection in Head-to-Head Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-16 22:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CU6.AU\">Clarity Pharmaceuticals</a>' 64Cu-SAR-bisPSMA Doubles Prostate Cancer Detection in Head-to-Head Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CLRPF\">Clarity Pharmaceuticals Ltd.</a> announced that data from the Co-PSMA Investigator-Initiated Trial (IIT), evaluating its diagnostic product 64Cu-SAR-bisPSMA in comparison to standard-of-care 68Ga-PSMA-11, will be presented at the European Association of Urology (EAU) Congress 2026. The study was conducted in 50 patients with biochemical recurrence of prostate cancer following radical prostatectomy. According to the released abstract, 64Cu-SAR-bisPSMA more than doubled prostate cancer lesion and patient detection rates compared to 68Ga-PSMA-11. Further data will be outlined following the oral presentation at EAU 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clarity Pharmaceuticals Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602160903PR_NEWS_USPR_____CN88550) on February 16, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7096","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260216:nNDL9Bks3h:1","article_id":"2611748526","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2611748526","pubTimestamp":1771250600,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Clarity Pharmaceuticals Ltd. announced that data from the Co-PSMA Investigator-Initiated Trial , evaluating its diagnostic product 64Cu-SAR-bisPSMA in comparison to standard-of-care 68Ga-PSMA-11, will be presented at the European Association of Urology  Congress 2026. The study was conducted in 50 patients with biochemical recurrence of prostate cancer following radical prostatectomy. According to the released abstract, 64Cu-SAR-bisPSMA more than doubled prostate cancer lesion and patient detection rates compared to 68Ga-PSMA-11. Further data will be outlined following the oral presentation at EAU 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7096":"制药","CU6.AU":"CLARITY PHARMACEUTICALS LTD"},"translate_title":"Clarity Pharmaceuticals的64Cu-SAR-bisPSMA在头对头试验中使前列腺癌检出率翻倍","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CU6.AU":0.9},"content_text":"Clarity Pharmaceuticals' 64Cu-SAR-bisPSMA Doubles Prostate Cancer Detection in Head-to-Head Trial\n    \n\nClarity Pharmaceuticals Ltd. announced that data from the Co-PSMA Investigator-Initiated Trial (IIT), evaluating its diagnostic product 64Cu-SAR-bisPSMA in comparison to standard-of-care 68Ga-PSMA-11, will be presented at the European Association of Urology (EAU) Congress 2026. The study was conducted in 50 patients with biochemical recurrence of prostate cancer following radical prostatectomy. According to the released abstract, 64Cu-SAR-bisPSMA more than doubled prostate cancer lesion and patient detection rates compared to 68Ga-PSMA-11. Further data will be outlined following the oral presentation at EAU 2026.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clarity Pharmaceuticals Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602160903PR_NEWS_USPR_____CN88550) on February 16, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}